美国食品和药物管理局批准了Moderna公司的新型COVID-19疫苗,适用于65岁以上的成年人和处于危险阶段的人. FDA approves Moderna's new COVID-19 vaccine for adults over 65 and at-risk individuals.

美国林业发展局批准了现代公司新的COVID-19疫苗MNEXSPIKE,对象是65岁及65岁以上的成年人和12至64岁具有潜在健康风险的个人。 The U.S. FDA has approved Moderna's new COVID-19 vaccine, mNEXSPIKE, for adults aged 65 and older and individuals aged 12 to 64 with underlying health risks. 批准是林业发展局收紧其疫苗核准标准以来的第一次批准。 The approval marks the first since the FDA tightened its vaccine endorsement criteria. 疫苗的效用和安全性与现代疫苗的原疫苗相当,可储存在标准冰箱中,使分发更加容易。 The vaccine, which shows comparable efficacy and safety to Moderna’s original vaccine, can be stored in standard refrigerators, making distribution easier.